What question did this study set out to answer?

This research aims to evaluate the reasons and clinical benefits for using bismuth subsalicylate during GLP-1 agonist therapy to manage sulfurous eructation.

March 13, 20260 citationsOpen Access

View Full Paper

Sulfurous Eructation During GLP-1 Agonist Therapy: Mechanistic Rationale for Bismuth Subsalicylate

YZYunus Emre Zahiroğlu

Key Points

This research aims to evaluate the reasons and clinical benefits for using bismuth subsalicylate during GLP-1 agonist therapy to manage sulfurous eructation.
Synthesis of existing evidence regarding GLP-1 and dual receptor agonists.
Assessment of bismuth subsalicylate's role in treating gastrointestinal side effects.
Exploration of mechanistic pathways behind sulfurous eructation.
Identified potential causes of sulfurous eructation linked to GLP-1 therapies.
Suggests bismuth subsalicylate may alleviate these gastric symptoms.
Highlights the need for further clinical investigation into bismuth subsalicylate's effectiveness.

Abstract

This pre-print presents a narrative evidence synthesis evaluating the mechanistic rationale and clinical implications of using bismuth subsalicylate (BSS) for sulfurous eructation associated with GLP-1 and dual GLP-1/GIP receptor agonists.

Perguntar à IA

Bookmark

View Full Paper

Cite This Study

Yunus Emre Zahiroğlu (Tue,) studied this question.

synapsesocial.com/papers/69b3acd302a1e69014ccedd6 https://doi.org/https://doi.org/10.5281/zenodo.18944854

Perguntar à IA

Bookmark

View Full Paper

Sulfurous Eructation During GLP-1 Agonist Therapy: Mechanistic Rationale for Bismuth Subsalicylate

Key Points

Abstract

Cite This Study

Also Consider

Also Consider